Arrowhead Pharmaceuticals Inc (ARWR)

Current ratio

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Total current assets	US$ in thousands	237,899	419,521	470,165	574,810	574,999	405,299	432,388	417,630	338,278	384,597	525,955	586,757	323,716	322,372	315,233	314,474	507,614	265,247	244,539	234,970
Total current liabilities	US$ in thousands	63,723	105,456	70,227	87,151	122,009	138,850	128,212	138,857	137,032	146,536	195,434	167,188	25,094	40,682	42,783	53,333	73,695	97,071	87,087	101,812
Current ratio		3.73	3.98	6.69	6.60	4.71	2.92	3.37	3.01	2.47	2.62	2.69	3.51	12.90	7.92	7.37	5.90	6.89	2.73	2.81	2.31

December 31, 2023 calculation

Current ratio = Total current assets ÷ Total current liabilities
= $237,899K ÷ $63,723K
= 3.73

Arrowhead Pharmaceuticals Inc. has exhibited fluctuations in its current ratio over the past eight quarters. The current ratio indicates the company's ability to cover its short-term obligations with its current assets.

In Q1 2024, the current ratio was 3.73, slightly lower than the previous quarter's ratio of 3.98 in Q4 2023. Despite this slight decrease, the company still maintains a healthy liquidity position.

The trend of the current ratio shows significant variability, with the ratio ranging from a high of 6.69 in Q3 2023 to a low of 2.92 in Q4 2022. A current ratio above 1 is generally considered favorable, as it indicates the company can meet its short-term liabilities.

Overall, Arrowhead Pharmaceuticals Inc. has shown varying levels of liquidity over the past quarters, with some quarters exhibiting stronger liquidity positions than others. It is essential for investors and stakeholders to monitor these fluctuations to assess the company's ability to meet its short-term obligations.